BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 17525129)

  • 1. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.
    May LT; Avlani VA; Langmead CJ; Herdon HJ; Wood MD; Sexton PM; Christopoulos A
    Mol Pharmacol; 2007 Aug; 72(2):463-76. PubMed ID: 17525129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors.
    Lanzafame AA; Sexton PM; Christopoulos A
    Mol Pharmacol; 2006 Aug; 70(2):736-46. PubMed ID: 16709648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.
    Avlani VA; Langmead CJ; Guida E; Wood MD; Tehan BG; Herdon HJ; Watson JM; Sexton PM; Christopoulos A
    Mol Pharmacol; 2010 Jul; 78(1):94-104. PubMed ID: 20413650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist.
    Langmead CJ; Fry VA; Forbes IT; Branch CL; Christopoulos A; Wood MD; Herdon HJ
    Mol Pharmacol; 2006 Jan; 69(1):236-46. PubMed ID: 16207821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators.
    May LT; Lin Y; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2005 Jan; 312(1):382-90. PubMed ID: 15333678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three allosteric modulators act at a common site, distinct from that of competitive antagonists, at muscarinic acetylcholine M2 receptors.
    Lanzafame A; Christopoulos A; Mitchelson F
    J Pharmacol Exp Ther; 1997 Jul; 282(1):278-85. PubMed ID: 9223565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor.
    Steinfeld T; Mammen M; Smith JA; Wilson RD; Jasper JR
    Mol Pharmacol; 2007 Aug; 72(2):291-302. PubMed ID: 17478612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.
    Jacobson MA; Kreatsoulas C; Pascarella DM; O'Brien JA; Sur C
    Mol Pharmacol; 2010 Oct; 78(4):648-57. PubMed ID: 20660086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of transmembrane domain 3 in the actions of orthosteric, allosteric, and atypical agonists of the M4 muscarinic acetylcholine receptor.
    Leach K; Davey AE; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2011 May; 79(5):855-65. PubMed ID: 21300722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.
    Avlani V; May LT; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1062-72. PubMed ID: 14711931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors.
    Lanzafame A; Christopoulos A
    J Pharmacol Exp Ther; 2004 Mar; 308(3):830-7. PubMed ID: 14617684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G protein coupling and signaling pathway activation by m1 muscarinic acetylcholine receptor orthosteric and allosteric agonists.
    Thomas RL; Mistry R; Langmead CJ; Wood MD; Challiss RA
    J Pharmacol Exp Ther; 2008 Nov; 327(2):365-74. PubMed ID: 18664591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.
    Thomas RL; Langmead CJ; Wood MD; Challiss RA
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1086-95. PubMed ID: 19767446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites.
    Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC
    Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of orthosteric radioligand depletion on the quantification of allosteric modulator interactions.
    Avlani VA; McLoughlin DJ; Sexton PM; Christopoulos A
    J Pharmacol Exp Ther; 2008 Jun; 325(3):927-34. PubMed ID: 18322151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor.
    Leppik RA; Miller RC; Eck M; Paquet JL
    Mol Pharmacol; 1994 May; 45(5):983-90. PubMed ID: 8190113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias.
    Gregory KJ; Hall NE; Tobin AB; Sexton PM; Christopoulos A
    J Biol Chem; 2010 Mar; 285(10):7459-74. PubMed ID: 20051519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the allosteric interactions of the bisquaternary heptane-1,7-bis(dimethyl-3'-phthalimidopropyl)ammonium bromide at M1 and M2 muscarine receptors.
    Christopoulos A; Mitchelson F
    Mol Pharmacol; 1994 Jul; 46(1):105-14. PubMed ID: 8058045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.
    Valant C; Felder CC; Sexton PM; Christopoulos A
    Mol Pharmacol; 2012 Jan; 81(1):41-52. PubMed ID: 21989256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.
    Keov P; Valant C; Devine SM; Lane JR; Scammells PJ; Sexton PM; Christopoulos A
    Mol Pharmacol; 2013 Sep; 84(3):425-37. PubMed ID: 23798605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.